306 related articles for article (PubMed ID: 31741284)
21. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
Springuel L; Renauld JC; Knoops L
Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
[TBL] [Abstract][Full Text] [Related]
22. STAT Transcription Factors in T Cell Control of Health and Disease.
Goswami R; Kaplan MH
Int Rev Cell Mol Biol; 2017; 331():123-180. PubMed ID: 28325211
[TBL] [Abstract][Full Text] [Related]
23. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
[No Abstract] [Full Text] [Related]
24. Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.
Bose S; Banerjee S; Mondal A; Chakraborty U; Pumarol J; Croley CR; Bishayee A
Cells; 2020 Jun; 9(6):. PubMed ID: 32545187
[TBL] [Abstract][Full Text] [Related]
25. Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
Lee K; Evans MG; Yang L; Ng S; Snowden C; Khodadoust M; Brown RA; Trum NA; Querfeld C; Doan LT; Song J; Zhang H; Gru AA; Wood GS; Wada DA; Shanmugam V; Haun PL; Aster JC; Duncan LM; Guitart J; Weinstock DM; Nardi V; Choi J
Blood; 2021 Dec; 138(23):2435-2440. PubMed ID: 34432866
[TBL] [Abstract][Full Text] [Related]
26. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
27. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms.
Hobbs GS; Hanasoge Somasundara AV; Kleppe M; Litvin R; Arcila M; Ahn J; McKenney AS; Knapp K; Ptashkin R; Weinstein H; Heinemann MH; Francis J; Chanel S; Berman E; Mauro M; Tallman MS; Heaney ML; Levine RL; Rampal RK
Haematologica; 2018 Jan; 103(1):e5-e9. PubMed ID: 29051283
[No Abstract] [Full Text] [Related]
28. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy.
Chen M; Wang S
Int Immunopharmacol; 2024 Mar; 130():111717. PubMed ID: 38387193
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms and consequences of Jak-STAT signaling in the immune system.
Villarino AV; Kanno Y; O'Shea JJ
Nat Immunol; 2017 Mar; 18(4):374-384. PubMed ID: 28323260
[TBL] [Abstract][Full Text] [Related]
30. The regulation of JAKs in cytokine signaling and its breakdown in disease.
Hammarén HM; Virtanen AT; Raivola J; Silvennoinen O
Cytokine; 2019 Jun; 118():48-63. PubMed ID: 29685781
[TBL] [Abstract][Full Text] [Related]
31. Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series.
Hu M; Liu R; Li J; Zhang L; Cao J; Yue M; Zhong D; Tang R
Ann Hematol; 2023 Sep; 102(9):2445-2457. PubMed ID: 37209119
[TBL] [Abstract][Full Text] [Related]
32. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Moskowitz AJ; Ghione P; Jacobsen E; Ruan J; Schatz JH; Noor S; Myskowski P; Vardhana S; Ganesan N; Hancock H; Davey T; Perez L; Ryu S; Santarosa A; Dowd J; Obadi O; Pomerantz L; Yi N; Sohail S; Galasso N; Neuman R; Liotta B; Blouin W; Baik J; Geyer MB; Noy A; Straus D; Kumar P; Dogan A; Hollmann T; Drill E; Rademaker J; Schoder H; Inghirami G; Weinstock DM; Horwitz SM
Blood; 2021 Dec; 138(26):2828-2837. PubMed ID: 34653242
[TBL] [Abstract][Full Text] [Related]
33. Canonical and non-canonical JAK-STAT signaling.
Li WX
Trends Cell Biol; 2008 Nov; 18(11):545-51. PubMed ID: 18848449
[TBL] [Abstract][Full Text] [Related]
34. A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer.
Arumuggam N; Bhowmick NA; Rupasinghe HP
Phytother Res; 2015 Jun; 29(6):805-17. PubMed ID: 25787773
[TBL] [Abstract][Full Text] [Related]
35. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
36. Drosophila Jak/STAT Signaling: Regulation and Relevance in Human Cancer and Metastasis.
Trivedi S; Starz-Gaiano M
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30558204
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of JAK/STAT signaling pathway prevents high-glucose-induced increase in endothelin-1 synthesis in human endothelial cells.
Manea SA; Manea A; Heltianu C
Cell Tissue Res; 2010 Apr; 340(1):71-9. PubMed ID: 20217138
[TBL] [Abstract][Full Text] [Related]
38. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
Derenzini E; Younes A
Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
[TBL] [Abstract][Full Text] [Related]
39. Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.
Manso R; Sánchez-Beato M; González-Rincón J; Gómez S; Rojo F; Mollejo M; García-Cosio M; Menárguez J; Piris MA; Rodríguez-Pinilla SM
Br J Haematol; 2018 Nov; 183(3):497-501. PubMed ID: 29076126
[No Abstract] [Full Text] [Related]
40. Tools and methods for studying the Drosophila JAK/STAT pathway.
Chen Q; Giedt M; Tang L; Harrison DA
Methods; 2014 Jun; 68(1):160-72. PubMed ID: 24685392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
